Journal of Clinical Microbiology · 2000 · 182 citations · 31 references
Life SciencesImmunologyInfectious DiseasesMolecular VirologyTransplant ImmunologyVirologyAllograft RejectionGraft-versus-host DiseaseMolecular Diagnostics In TransplantationPositive Predictive ValuePositive Predictive Value AnalysisPositive Predictive Value EstimationViral Serology Screening
Epstein-Barr virus (EBV) DNA was quantitated in peripheral blood mononuclear cells (PBMC) from 25 healthy subjects, 105 asymptomatic solid-organ transplant (SOT) recipients, and 15 SOT recipients with symptomatic EBV infections by using a newly developed quantitative-PCR technique. Patients with symptomatic EBV infections had significantly higher (P < 0.001) median EBV DNA levels than asymptomatic SOT recipients and immunocompetent individuals. In SOT recipients, the positive predictive value of EBV DNA levels of >1, 000 genome equivalents (GE)/0.5 microg of total PBMC DNA was 64.7% for symptomatic EBV infection, while the negative predictive value was 96.1%. In 19 of 32 (59.3%) asymptomatic SOT recipients, EBV DNA levels were consistently below 1,000 GE for as long as 18 months, while 10 of 32 (31.2%) patients had 1,000 to 5,000 EBV GE at least once during follow-up. In a minority of patients (3 of 32; 9.3%), >/=5,000 GE could be detected at least once during follow-up. Reduction of immunosuppressive treatment decreased EBV DNA levels by >/=1 log(10) unit in patients with symptomatic EBV infections. Quantification of EBV DNA is valuable for the diagnosis and monitoring of symptomatic EBV infections in SOT recipients.
31
Lode J. Swinnen, Maria Rosa Costanzo‐Nordin, Susan G. Fisher et al. · New England Journal of Medicine · 1990 · 953 citations